Mr. Jim Durward reports

NDATALYZE CORP. ("NDAT" OR THE "CORPORATION") (CSE:NDAT) (OTC:NDATF) DNA CLINICAL STUDY AND MINDBALANCED OPERATIONAL UPDATE

Ndatalyze Corp. has provided updates on its DNA-related clinical study and Mindbalanced operations.

The clinical study

The corporation's belief is that, while genetic predispositions can make individuals more susceptible to certain mental health issues, environmental factors play a crucial role in whether these conditions develop and how they progress. For instance, a person with a genetic predisposition to depression may or may not develop the condition depending on their life experiences and other environmental influences. The corporation also believes that understanding the interplay between genetics and environment is important to better assess mental health issues and develop effective treatments. The essence of the clinical study with York University is to investigate the relationship between certain DNA aspects and the extensive environmental factors resident in the records of the company's reference database when predicting probabilities of depression. Based on results to date, the corporation believes, when using psychiatrist/psychologist diagnoses as the ground truth, the inclusion of DNA data results in more comprehensive and nuanced predictions, returning up-to-90-per-cent positive predictive values depending on optimal tuning and using the current DNA panel.

It is believed that a variety of currently available DNA panels can be incorporated, thereby increasing nuance for various medical condition/DNA relationships. It was also found that after the DNA-enhanced model was completed, a different model employing only life/environmental factors and using the same ground truth could predict similar positive predictive values, implying that the different model can return high-accuracy analyses without DNA data. These data analysis models do not constitute diagnoses; but, rather, the predicted probabilities may be considered adjunctive when informing diagnoses and associated treatment programs.

Jim Durward, chief executive officer and chief technology officer, stated: "Although the clinical study is first focused on depression and uses a pharmacogenomic DNA panel, we now believe that the overall process can accommodate other DNA panels that are used in the investigation of drug interactions and neurological predispositions. I am very excited about the potential here."

Mindbalanced (MB) operations

During the three months since the acquisition, MB has been organizing its operations under a franchise-style business model that involves standardized service relationships with clients, DNA data collection and FDA-cleared (U.S. Food and Drug Administration) transcranial magnetic stimulation (TMS) treatments for certain mental conditions. The overall concept is to combine the corporation's data expertise and databases with new DNA and TMS treatment data to help design personalized treatments for a variety of mental conditions. During the period, contracts were constructed to allow for regulatory variations between U.S. states, a sales pipeline was established, and, on Monday, July 15, 2024, a contract was signed with Incite Health Inc. (IHI), whereby MB will provide marketing and account management services related to IHI's DNA panel offerings.

Joshua Hill, president, stated: "This strategic relationship is not only expected to become a material near-term revenue generator but also carries significant potential to expand the corporation's reference database with DNA-enhanced records, which we believe can be combined with TMS treatment data to generate highly personalized treatment plans."

About YMI

YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge toward a fuller understanding of how mental health develops and how to improve mental well-being. YMI combines supervised machine learning with a proprietary reference database to predict an individual's predisposition toward a variety of common mental conditions, both current and forward in time.

YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies and targeting key markets, YMI aligns both societal impact and financial success.

About Mindbalanced Inc.

Mindbalanced's vision is to redefine mental health care through an integrative, personalized approach leveraging cutting-edge technology and non-invasive treatment protocols. By harnessing evidence-based data, Mindbalanced aims to predict and enhance mental well-being, taking into account individual predispositions and environmental factors and thereby fostering healthier and more fulfilling lives for all.

We seek Safe Harbor.